查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002976

開放性青光眼治療市場：依藥物類別、治療方法、給藥途徑、通路及最終用戶分類－2026-2032年全球市場預測

Open-Angle Glaucoma Therapeutics Market by Drug Class, Therapy Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年開放性青光眼治療市場價值為 102 億美元，預計到 2026 年將成長至 111.2 億美元，複合年成長率為 9.06%，到 ​​2032 年將達到 187.3 億美元。

主要市場統計數據
基準年 2025 102億美元
預計年份：2026年 111.2億美元
預測年份 2032 187.3億美元
複合年成長率 (%) 9.06%

對不斷發展的開放性青光眼。

開放性青光眼仍然是全球範圍內導致不可逆性視力喪失的主要原因之一，治療方法也在不斷發展，以滿足未被滿足的需求並適應技術進步。近年來，該領域的治療方法已從單純以眼壓為中心的策略轉向多方面綜合策略，包括神經保護、患者用藥依從性和聯合治療。這拓寬了臨床醫生和保險公司在實務中評估新藥和給藥方法時所依據的證據基礎。

機制創新、先進的管理技術以及支付方期望的變化，正在從根本上重塑開放性青光眼。

開放性青光眼的治療格局正經歷著一場變革，這場變革是由科學、臨床和商業性因素共同推動的。作用機制的創新，特別是Rho激酶抑制劑和其他標靶小梁網房水流出路徑藥物的出現，正在挑戰傳統藥物長期以來的主導地位，並促使人們進行直接的療效比較評估。同時，製劑和給藥方法的改進，例如緩釋植入植入和不含防腐劑的眼藥水，正在重塑患者的用藥依從性和臨床實踐。

2025 年關稅對供應鏈變化帶來的實際影響，以及為維持治療的可及性、連續性和商業性勢頭而採取的策略應對措施。

2025年即將實施的新關稅將進一步增加治療藥物和醫療設備的商業複雜性，這些藥物和醫療器材依賴來自世界各地的零件和活性成分。進口關稅的增加推高了原料和成品的採購成本，促使採購團隊重新評估其供應商組合，並考慮雙重採購和地域多元化策略，以維持盈利能力和供應的連續性。為此，一些製造商正在加速推動近岸外包和契約製造夥伴關係，以降低關稅波動帶來的風險。

細分市場證據優先事項和商業化槓桿源自於藥物類別、治療方法類型和給藥途徑，這些因素決定了治療藥物的差異化。

精準理解藥物細分對於合理定位資產、優先考慮跨藥物類別、治療方法類型和給藥途徑的臨床和商業投資至關重要。在各類藥物中，應考慮許多研究領域，包括α受體阻斷劑、 BETA阻斷劑、碳酸酐酶抑制劑、固定劑量組合藥物、前列腺素類似物和Rho激酶抑制劑。 BETABETA阻斷劑類別再細分為倍他洛爾、美替洛爾和噻嗎洛爾，而前列腺素類似物則包括Bimatoprost、拉坦前列素、他氟前列素和曲伏前列素。這些區分至關重要，因為機制特異性的安全性和耐受性特徵以及潛在的差異化優勢會影響關於臨床定位和處方集的討論。

美洲、歐洲、中東和非洲以及亞太地區在監管、支付方框架和供應鏈趨勢方面的細微差異，如何影響差異化的市場進入和成長策略？

區域趨勢對監管路徑、報銷方式和商業性實施有顯著影響，因此美洲、歐洲、中東、非洲和亞太地區需要製定量身定做的策略。在美洲，價格談判、支付方協議和病患支援體係是影響藥物可及性和推廣的關鍵因素，而臨床實務模式和眼科轉診網路則決定了新型作用機制和緩釋製劑的採納曲線。

一種競爭定位和夥伴關係模式，能夠使青光眼治療領域的相關人員（製藥公司、生物技術公司和醫療設備製造商）實現永續的差異化。

開放性青光眼治療市場的競爭格局由大型製藥企業、專業生物技術公司和醫療設備製造商組成，它們各自尋求在臨床和商業上脫穎而出的途徑。成熟的大型公司通常利用其廣泛的分銷網路、臨床試驗經驗和與支付方的良好關係來支援漸進式創新和生命週期管理。相較之下，規模較小的生物技術公司則專注於具有單一作用機制的突破性成果、靈活的研發進度以及策略夥伴關係，以降低規模化生產和市場准入方面的風險。

針對研發、商業規劃和供應鏈韌性等方面的優先考慮，提出了極具影響力和可操作性的建議，以加快招聘速度並確保就業機會。

產業領導企業應採取協作策略，將科學差異化、商業性執行和供應鏈韌性結合在一起。優先開發那些與現有標準療法相比具有明顯耐受性和依從性優勢的藥物，並設計臨床試驗以獲得對臨床醫生、支付方和患者都有意義的終點指標。這包括將生活品質 (QOL) 和依從性指標納入主要試驗，並規劃從早期階段就收集真實世界數據 (REW)。

一種透明且可重複的調查方法，將與專家的直接訪談與全面的二手證據相結合，以支持策略決策。

本報告整合了第一手和第二手研究方法，建構了一個穩健且多方驗證的證據基礎。第一手研究包括對臨床醫生、支付方、採購專業人員和行業高管進行結構化訪談，並輔以諮詢委員會的意見和來自銷售團隊的實地洞察。第二手研究則利用了同行評審文獻、監管指導文件、臨床試驗註冊信息以及公開的企業資訊披露，以分析臨床開發趨勢和市場准入促進因素。

這明確地整合了領導者必須解決的營運挑戰，以將治療方法創新、證據優先排序和進展轉化為永續的臨床和商業性成功。

總而言之，開放性青光眼治療市場正進入一個機會與挑戰並存的階段，其促進因素包括作用機制的創新、給藥方式的進步以及支付方期望的轉變。能夠整合差異化臨床價值、永續給藥方案和可靠的真實世界證據的公司，將更有利於影響臨床實踐並確保獲得報銷。同時，貿易趨勢和區域差異也要求企業制定積極主動的供應鏈規劃和區域性市場策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：開放性青光眼治療市場：依藥物類別分類

  • α-激動劑
  • BETA阻斷劑
    • 倍他索
    • 甲羥戊酸
    • 蒂莫羅爾
  • 碳酸酐酶抑制劑
  • 固定劑量組合藥物
  • 前列腺素類似物
    • Bimatoprost
    • 拉坦前列素
    • 塔福普羅斯特
    • 曲前列素
  • Rho激酶抑制劑

第9章：依治療方法開放性青光眼治療市場

  • 聯合治療
    • BETA阻斷劑與攝護腺素
    • 碳酸酐酶抑制劑和BETA阻斷劑
  • 單藥治療

第10章：開放性青光眼治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 局部的

第11章：開放性青光眼治療市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 專科藥房
  • 郵購藥房

第12章：開放性青光眼治療市場：依最終用戶分類

  • 醫院
    • 三級醫療機構
    • 當地醫院
  • 門診手術中心
  • 眼科診所
  • 驗光診所
  • 學術和研究機構

第13章：開放性青光眼治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章開放性青光眼治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：開放性青光眼治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國開放性青光眼治療市場

第17章：中國開放性青光眼治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Aerie Pharmaceuticals, Inc.
  • Alcon Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-957C47F9384B

The Open-Angle Glaucoma Therapeutics Market was valued at USD 10.20 billion in 2025 and is projected to grow to USD 11.12 billion in 2026, with a CAGR of 9.06%, reaching USD 18.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.20 billion
Estimated Year [2026] USD 11.12 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.06%

A concise and authoritative orientation to the evolving therapeutic landscape, unmet needs, and strategic imperatives shaping open-angle glaucoma care

Open-angle glaucoma remains a leading cause of irreversible vision loss worldwide, and therapeutics development continues to evolve in response to unmet clinical needs and technological progress. In recent years, the field has witnessed a shift from solely intraocular pressure-centric approaches to multidimensional strategies that consider neuroprotection, patient adherence, and combination regimens. This has broadened the evidence base that clinicians and payers evaluate when integrating new agents and delivery modalities into practice.

The introduction of novel mechanisms of action, advances in sustained-delivery systems, and an expanding emphasis on real-world outcomes have collectively reshaped clinical expectations and commercial models. Consequently, stakeholders across pharmaceutical, biotechnology, and medical device sectors are re-evaluating go-to-market plans, evidence-generation strategies, and partnerships. This introduction sets the stage for a focused exploration of the transformative shifts, regulatory and trade dynamics, segmentation nuances, regional considerations, and strategic actions that will define the therapeutic landscape in the near term.

How mechanistic innovation, advanced delivery technologies, and evolving payer expectations are fundamentally reshaping open-angle glaucoma therapeutic strategy and adoption

The therapeutic landscape for open-angle glaucoma is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Mechanistic innovation, particularly the emergence of Rho kinase inhibitors and other agents targeting trabecular outflow, challenges the long-standing dominance of traditional classes and invites head-to-head comparative effectiveness assessments. At the same time, improvements in drug formulation and delivery - including sustained-release implants and preservative-free topical options - are reshaping adherence patterns and clinical practice.

Concurrently, payer expectations and regulatory pathways are evolving, incentivizing robust real-world evidence and health-economic evaluations. Innovations in diagnostics, such as enhanced imaging and home-monitoring technologies, are enabling earlier detection and more individualized treatment adjustments. These combined trends are prompting a strategic realignment across life sciences companies and clinics: research and development pipelines are being prioritized for agents with demonstrable durability and tolerability advantages, commercial models are emphasizing patient support and adherence solutions, and partnerships between pharmaceutical and device manufacturers are becoming more common to deliver integrated care solutions.

Practical implications of tariff-driven supply chain shifts in 2025 and strategic responses that preserve access, continuity, and commercial momentum for therapeutics

The imposition of new tariffs in 2025 has introduced an additional layer of commercial complexity for therapeutics and devices that rely on globally sourced components and active pharmaceutical ingredients. Increased duties on imports can elevate the landed cost of raw materials and finished products, prompting procurement teams to reassess supplier portfolios and consider dual sourcing or regionalization strategies to preserve margin and supply continuity. In response, some manufacturers are accelerating nearshoring and contract manufacturing partnerships to mitigate exposure to tariff volatility.

Beyond direct cost impacts, tariffs influence strategic timelines and product launch sequencing. Companies may adjust supply chain footprints to prioritize markets with lower trade friction or to insulate critical production lines from tariff-related disruptions. This environment also amplifies the importance of contractual protections, such as long-term supply agreements and price adjustment clauses. From a clinical perspective, tariffs can indirectly affect access by increasing list prices or constraining the availability of certain imported formulations, thereby necessitating expanded patient assistance programs and adaptive reimbursement negotiations. Overall, the tariff landscape underscores the need for dynamic commercial strategies that integrate trade risk assessment, supply chain resilience, and proactive stakeholder engagement.

Segment-specific evidence priorities and commercialization levers drawn from drug classes, therapy types, and administration routes that shape therapeutic differentiation

A nuanced understanding of segmentation is essential to position assets and prioritize clinical and commercial investments across drug classes, therapy types, and routes of administration. Based on drug class, study considerations span Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, Fixed Dose Combinations, Prostaglandin Analogues, and Rho Kinase Inhibitors, with the Beta Blockers category further disaggregated into Betaxolol, Metipranolol, and Timolol, and Prostaglandin Analogues examined across Bimatoprost, Latanoprost, Tafluprost, and Travoprost. These distinctions matter because mechanism-specific safety and tolerability profiles, as well as differentiation potential, influence clinical positioning and formulary discussions.

Based on therapy type, the market perspective encompasses Combination Therapy and Monotherapy, where Combination Therapy merits closer scrutiny for regimens such as Beta Blocker And Prostaglandin and Carbonic Anhydrase Inhibitor And Beta Blocker. Combination strategies often seek to improve intraocular pressure control while simplifying regimens to enhance adherence, which can materially affect real-world effectiveness. Based on route of administration, the clinical and commercial dialogue must address Intravenous, Oral, and Topical approaches, each of which carries unique considerations for delivery technology, patient acceptance, safety monitoring, and distribution logistics. Taken together, segmentation insights should drive targeted evidence generation and commercial differentiation for any candidate therapy.

How regional regulatory nuances, payer frameworks, and supply chain dynamics across the Americas, EMEA, and Asia-Pacific inform differentiated market entry and growth strategies

Regional dynamics materially influence regulatory pathways, reimbursement approaches, and commercial execution, requiring tailored strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, pricing negotiations, payer contracting, and patient support infrastructure are critical determinants of access and uptake, while clinical practice patterns and ophthalmology referral networks shape the adoption curve for new mechanisms and sustained-delivery systems.

In Europe, Middle East & Africa, diverse regulatory regimes and reimbursement criteria necessitate robust health-economic dossiers and region-specific real-world evidence. Market entry strategies must account for heterogeneous procurement processes and variable hospital purchasing practices across countries. In the Asia-Pacific region, regulatory modernization, growing biotech investment, and a rising focus on locally manufactured products create opportunities for collaboration and regional manufacturing. Across all geographies, supply chain resilience, local clinical data generation, and culturally attuned patient support programs are core enablers of sustained adoption and commercial success.

Competitive positioning and partnership models that enable durable differentiation across pharmaceutical, biotech, and device stakeholders in glaucoma therapeutics

Competitive dynamics in the open-angle glaucoma therapeutics space are shaped by a mix of large pharmaceutical companies, specialty biotechs, and device-focused manufacturers, each pursuing distinct routes to clinical and commercial differentiation. Established players typically leverage broad distribution networks, clinical trial experience, and payer relationships to support incremental innovations and lifecycle management. In contrast, smaller biotechs emphasize single-mechanism breakthroughs, nimble development timelines, and strategic partnerships to de-risk scale-up and access pathways.

Collaboration models are increasingly prevalent: co-development and licensing agreements bring together formulation expertise, delivery platforms, and commercialization capabilities. Meanwhile, device manufacturers that deliver sustained-release implants or novel administration systems are collaborating with drug developers to offer integrated solutions that address adherence and durability. Successful companies are those that align clinical development with pragmatic evidence generation, engage early with payers and key opinion leaders, and invest in patient-centric support services that reinforce real-world outcomes and reduce treatment discontinuation.

High-impact, actionable recommendations for R&D prioritization, commercial planning, and supply chain resilience to accelerate adoption and protect access

Industry leaders should pursue a coordinated strategy that aligns scientific differentiation with commercial execution and supply chain resilience. Prioritize development programs that address clear tolerability or adherence advantages over existing standards of care and design clinical trials to capture endpoints meaningful to clinicians, payers, and patients. This includes integrating quality-of-life measures and adherence metrics into pivotal studies and planning for real-world evidence generation from the outset.

From a commercial perspective, invest in patient support systems, clinician education, and value demonstration to build compelling reimbursement narratives. Strengthen supplier relationships and diversify manufacturing footprints to mitigate tariff and trade risks, and evaluate regional manufacturing or contract development and manufacturing organization partnerships where appropriate. Pursue strategic collaborations that combine delivery technology with pharmacologic innovation, and engage payers early to align on evidence requirements and pricing strategies. Finally, maintain adaptive launch sequencing and portfolio prioritization that reflects regional regulatory timelines, procurement environments, and local clinical practice patterns.

Transparent and reproducible research methods combining expert primary interviews and comprehensive secondary evidence to inform strategic decision-making

The report synthesizes primary and secondary research methods to create a robust, triangulated evidence base. Primary research included structured interviews with clinicians, payers, procurement specialists, and industry executives, complemented by advisory-board consultations and field-level insights from commercial teams. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to contextualize clinical development trends and market-access drivers.

Data from these sources were triangulated to reconcile differing perspectives and validate strategic conclusions. Quality-control measures included cross-validation of interview findings, reproducibility checks for analytical models, and a governance process for expert review. Where gaps existed, targeted follow-up interviews were conducted to ensure the analysis reflected current practice and regulatory dynamics. The methodology emphasizes transparency and reproducibility while prioritizing practical insights that inform clinical development, commercialization, and policy strategy.

A conclusive synthesis of therapeutic innovation, evidence priorities, and operational imperatives that leaders must address to translate advances into sustained clinical and commercial success

In summary, the open-angle glaucoma therapeutics landscape is entering a phase where mechanistic innovation, delivery advances, and evolving payer expectations converge to create both opportunity and complexity. Companies that integrate differentiated clinical value with durable delivery solutions and robust real-world evidence will be best positioned to influence clinical practice and secure reimbursement. Simultaneously, trade dynamics and regional heterogeneity require proactive supply chain planning and localized market strategies.

Achieving sustained impact will depend on aligning R&D priorities with pragmatic evidence generation, engaging stakeholders across the care pathway early, and deploying patient-centric commercial programs that support adherence and long-term outcomes. Decision-makers who adopt an integrated approach-combining scientific differentiation, commercial rigor, and operational resilience-will be able to translate therapeutic innovation into improved patient care and durable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Open-Angle Glaucoma Therapeutics Market, by Drug Class

  • 8.1. Alpha Agonists
  • 8.2. Beta Blockers
    • 8.2.1. Betaxolol
    • 8.2.2. Metipranolol
    • 8.2.3. Timolol
  • 8.3. Carbonic Anhydrase Inhibitors
  • 8.4. Fixed Dose Combinations
  • 8.5. Prostaglandin Analogues
    • 8.5.1. Bimatoprost
    • 8.5.2. Latanoprost
    • 8.5.3. Tafluprost
    • 8.5.4. Travoprost
  • 8.6. Rho Kinase Inhibitors

9. Open-Angle Glaucoma Therapeutics Market, by Therapy Type

  • 9.1. Combination Therapy
    • 9.1.1. Beta Blocker And Prostaglandin
    • 9.1.2. Carbonic Anhydrase Inhibitor And Beta Blocker
  • 9.2. Monotherapy

10. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Topical

11. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Specialty Pharmacies
  • 11.5. Mail-Order Pharmacies

12. Open-Angle Glaucoma Therapeutics Market, by End User

  • 12.1. Hospitals
    • 12.1.1. Tertiary Care Hospitals
    • 12.1.2. Community Hospitals
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Ophthalmology Specialty Clinics
  • 12.4. Optometry Practices
  • 12.5. Academic And Research Centers

13. Open-Angle Glaucoma Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Open-Angle Glaucoma Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Open-Angle Glaucoma Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Open-Angle Glaucoma Therapeutics Market

17. China Open-Angle Glaucoma Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Aerie Pharmaceuticals, Inc.
  • 18.7. Alcon Inc.
  • 18.8. Merck & Co., Inc.
  • 18.9. Novartis AG
  • 18.10. Pfizer Inc.
  • 18.11. Santen Pharmaceutical Co., Ltd.
  • 18.12. Sun Pharmaceutical Industries Ltd.
  • 18.13. Teva Pharmaceutical Industries Ltd.
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPTOMETRY PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPTOMETRY PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPTOMETRY PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 203. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 233. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 243. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)